| abstract |
NUCLEAR RECEPTOR BINDING AGENTS. The present invention relates to the new class of nuclear receptor binding agents (NRBAs). NRBAs are applicable in the use of the prevention and / or treatment of several diseases and disorders, including, among others, the prevention and treatment of cancers, such as prostate and breast cancer, osteoporosis, hormone-related diseases, inflammatory diseases, relative diseases to oxidative stress, such as Parkinson's and stroke, neurological disorders, ophthalmic disorders, cardiovascular disease and obesity. |